Fusion Antibodies Share Discussion Threads

[gimmetheloot] 18/9/2020 16:24

Wait till the media get on this, they will be all over it on the weekend. This will save lives save people from serious illness and prevent lockdowns.

[inthemix] 18/9/2020 16:23

Glad it dropped back, managed to get onboard.

[ic0gcds00] 18/9/2020 16:11

Think I might regret that next week

[trigger blade] 18/9/2020 16:04

Particularly relevant in Todger148’s case xTomo, because in his 35 pages of posts in 10 days, they’re all big deramps of shares. Then he turns up here out of the blue, having just sold out at the day’s high. Quite remarkable!

[phil1969] 18/9/2020 16:00

Don't normally average up, couldn't resist as day traders exit and free up stock. Added another 6,000

[xtomo] 18/9/2020 15:40

I love the way peeps grandly announce their trades well after the event.. if it looks ok. If you're confident, tell us as it happens and you'll have more credibility. I recklessly sold at 212 and was happy, but the subsequent rise made me drink the celebratory bottle of wine in one go ?( drown sorrows) Buy order in for 95.

[billthebank] 18/9/2020 15:35

Roger I did too. Put it in GDR!!!

[roger148] 18/9/2020 15:24

Managed to get out at 240pLets see could drop a little more now

[tidy 2] 18/9/2020 14:27

Will rise with a bit of sideways now.

[letmepass] 18/9/2020 14:05

Not a bad day already. Out for now back in at 100p

[tidy 2] 18/9/2020 13:54

The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.

[billthebank] 18/9/2020 13:16

GDR abd DDDD also going mental.WOW!!!

[ic0gcds00] 18/9/2020 13:13

Looks prime takeover opportunity for big pharma

[phil1969] 18/9/2020 13:11

Strongest buy and hold I've found for a while. I can't find a downside from this level other than daytraders shifting the price around but that's just noise.

[billthebank] 18/9/2020 13:02

Holy Moly.Bought some on a wing and a prayer at 200

[tomboyb] 18/9/2020 12:58

looking v strong -

[gwr7] 18/9/2020 12:52

Jumping the gun a little but couldn't resist.

GWR7 17 Apr '20 - 10:00 - 46 of 49
When I suggested you hold on for the ride I meant more than ten minutes. The CEO gave more information than provided in the RNS. Let's reconvene in 6 months and see who was right. Price currently 116p.

[tidy 2] 18/9/2020 12:48

700p ps should come with easy cap wise it will be 150m

[phil1969] 18/9/2020 12:46

Nice bit of consolidation at £2. When I bough in earlier this morning I thought I'd hold this for a couple of weeks but now I've spent more time digging, looks like this is set to run for the rest of 2020 if the updates keep coming.

[tidy 2] 18/9/2020 12:29

This news is related to FAB with Roche hTTps://www.globenewswire.com/news-release/2020/09/18/2095622/0/en/Roche-launches-new-quantitative-antibody-test-to-measure-SARS-CoV-2-antibodies-to-support-the-evaluation-of-vaccines.htmlhTTps://www.globenewswire.com/news-release/2020/09/18/2095622/0/en/Roche-launches-new-quantitative-antibody-test-to-measure-SARS-CoV-2-antibodies-to-support-the-evaluation-of-vaccines.htmlBasel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response.1 Specifically, the test targets antibodies which are directed against the particular region of the viral spike protein responsible for binding to the host cell receptor, which is required for the virus to enter the host cell. The majority of current candidate vaccines aim to induce an antibody response against the spike protein."As the possibility of an effective SARS-CoV-2 vaccine becomes a reality, quantitative measurement of antibodies will be crucial in the evaluation of any potential vaccine. The new quantitative Elecsys antibody test can play a pivotal role in vaccine clinical trials as well as helping clinicians assess patients immune response.This will be instrumental in protecting people most vulnerable to the virus, as well as in overcoming COVID-19 for society in general." said Thomas Schinecker, CEO Roche Diagnostics. "This new test, the twelfth in the Roche SARS-CoV-2 testing portfolio, is another essential addition to support healthcare systems and patients as we jointly fight COVID-19."

[tomboyb] 18/9/2020 12:25

Its looking v interesting -

Not new to FAB as i initially bought at around the 80p levels but sold out -

However in today early so looking forward to see what transpires -

[tidy 2] 18/9/2020 12:19

Market radars totally blindsided by this news and company for that matter. Tiny free float tiny cap. Base 700p ps imo.

[superg1] 18/9/2020 12:18

Tidy

I did spot that but didn't research it, too busy and now on other bits today.

But in theory big pharma will sign up and I see no reason, based on others why this shouldn't hit £150mill to £200mill MC in short order.

It will take a while for investors to realise the basics of the business and that no big raises are needed at all.

On the face of it the antigens alone look like they beat what others are doing.